Immix Biopharma, Inc. (IMMX)
Automate Your Wheel Strategy on IMMX
With Tiblio's Option Bot, you can configure your own wheel strategy including IMMX - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol IMMX
- Rev/Share 0.0
- Book/Share 0.323
- PB 7.2445
- Debt/Equity 0.1104
- CurrentRatio 1.8028
- ROIC -2.0475
- MktCap 65232866.0
- FreeCF/Share -0.4511
- PFCF -4.8693
- PE -3.3259
- Debt/Assets 0.0532
- DivYield 0
- ROE -1.3002
- Rating C
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 3
- P/B Score 1
- D/E Score 3
Recent Analyst Ratings
Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
---|---|---|---|---|---|---|---|
No ratings available. |
News
Immix Biopharma Further Expands U.S. Clinical Sites for relapsed/refractory AL Amyloidosis Trial NEXICART-2
Published: May 23, 2025 by: GlobeNewsWire
Sentiment: Neutral
– Patient enrollment exceeding expectations – – 14 U.S. sites actively enrolling; 10 U.S. sites added since last update – – Anticipate completing NEXICART-2 clinical trial ahead of schedule – LOS ANGELES, CA, May 23, 2025 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us” or "IMMX”), a clinical-stage biopharmaceutical company developing cell therapies for AL Amyloidosis and other serious diseases, today announced that 14 U.S. sites are actively enrolling in U.S. multi-site study NEXICART-2. This milestone adds 10 sites since the Company's most recent update.
Read More
About Immix Biopharma, Inc. (IMMX)
- IPO Date 2021-12-16
- Website https://www.immixbio.com
- Industry Biotechnology
- CEO Dr. Ilya Rachman M.B.A., M.D., MBA, Ph.D.
- Employees 18